Consolidated condensed balance sheets - USD ($) $ in Thousands	Apr. 02, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 27,374	$ 43,933
Restricted cash	5,280	5,280
Accounts receivable, net	119,288	124,963
Inventory	64,691	61,688
Prepaid and other current assets	28,762	27,239
Total current assets	245,395	263,103
Restricted cash, less current portion	50,000	50,000
Property and equipment, net	24,856	22,985
Goodwill	147,968	147,623
Intangible assets, net	681,369	695,193
Operating lease assets	18,738	17,186
Deferred tax assets	0	481
Investment and other assets	28,811	29,291
Total assets	1,197,137	1,225,862
Current liabilities:
Accounts payable	22,500	16,915
Accrued liabilities	124,804	131,473
Accrued equity-based compensation	0	10,875
Current portion of long-term debt	20,292	18,038
Other current liabilities	3,926	3,558
Total current liabilities	171,522	180,859
Long-term debt, less current portion	348,039	339,644
Deferred income taxes	116,020	133,518
Contingent consideration	16,598	16,329
Other long-term liabilities	23,040	21,723
Total liabilities	675,219	692,073
Commitments and contingencies
Stockholders’ Equity:
Additional paid-in capital	467,940	465,272
Accumulated deficit	(17,879)	(6,602)
Accumulated other comprehensive (loss) income	(363)	179
Total stockholders’ equity attributable to Bioventus Inc.	449,776	458,924
Noncontrolling interest	72,142	74,865
Total stockholders’ equity	521,918	533,789
Total liabilities and stockholders’ equity	1,197,137	1,225,862
Common Class A
Stockholders’ Equity:
Common stock, value	62	59
Common Class B
Stockholders’ Equity:
Common stock, value	$ 16	$ 16